secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0000950170-25-044764
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences FY2024 net income $7.2M; PBGENE-HBV Phase 1 shows HBsAg reduction
--------------------------------------------------------------------------------

- Q4 2024 net loss $17.8M ($2.22/sh) vs $16.3M loss in Q4 2023; FY2024 net income $7.2M vs FY2023 loss $61.3M.
- Cash, equivalents $108.5M at Dec 31, 2024; cash runway expected into H2 2026.
- PBGENE-HBV Phase 1 low-dose cohort (N=3) dosed; well-tolerated with no grade ≥2 AE; 2 of 3 patients showed substantial HBsAg reduction.
- Partner iECURE reported complete clinical response in first infant dosed for OTC deficiency; ECUR-506 generally well tolerated.
- Appointed Cindy Atwell as Chief Development and Business Officer and Dr. Cassie Gorsuch as Chief Scientific Officer in Jan 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017025044764/0000950170-25-044764-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017025044764/dtil-20250326.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-044764

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer